We offer expert, comprehensive consultation on complex psychiatric cases. A referral from the primary psychiatric clinician is required. You can contact us at email@example.com or at 203-688-9719 for more information.
The Yale Department of Psychiatry has been at the forefront of research into the use of brain stimulation therapy to treat disorders like depression, schizophrenia, and bipolar disease. In the late-1990s, Yale researchers were the first to discover that the drug ketamine, which is primarily used to induce and maintain anesthesia, provided rapid relief to some chronically depressed patients who did not respond to traditional medication. In March 2019, Esketamine (Spravato) was approved by the US Food and Drug Administration (FDA) for the treatment of depression and YNHPH is one of the few sites in Connecticut that offers this treatment.
If considered an appropriate treatment option after a thorough evaluation process, IPS offers Esketamine and ketamine treatments in a safe, monitored environment administered by highly experienced physicians.
Yale IPS also offers Transcranial Magnetic Stimulation (TMS), which is used for patients with serious depressive disorders who have not improved with various antidepressants. It does not require hospitalization, anesthesia or a drug regime, but uses brief magnetic fields, not unlike those used in diagnostic magnetic resonance imaging (MRI).
offers electroconvulsive therapy (ECT) for patients diagnosed with severe depression and certain other mental disorders, including bipolar disorder or schizoaffective disorder. Available on both an inpatient and outpatient basis, ECT is a safe and effective treatment. ECT is administered by our team of specially trained psychiatrists, registered nurses and anesthesiologists, following the standards of Electroconvulsive Therapy Practice developed by the American Psychiatric Association.